Savara Inc.
Clinical trials sponsored by Savara Inc., explained in plain language.
Savara Inc.
SVRA
NASDAQ
A biopharmaceutical company developing inhaled therapies for rare respiratory diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for kids with rare lung condition: inhaled protein therapy in trial Results expected Jun 2027 (estimated)